AZNCF Dividend: AstraZeneca PLC Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

AZNCF Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	58,127	54,073	45,811	44,351	37,417	26,617
Revenue Growth (YoY)	14%	18%	3%	19%	41%	9%
Cost of Revenue	10,523	9,658	8,068	8,649	9,542	5,270
Gross Profit	47,604	44,415	37,743	35,702	27,875	21,347
Selling, General & Admin	15,837	15,495	14,649	13,512	11,519	9,338
Research & Development	13,664	12,211	10,271	9,612	8,519	6,094
Operating Expenses	33,454	31,732	28,827	26,874	22,973	16,948
Other Non Operating Income (Expenses)	--	-291	-457	-441	-502	-530
Pretax Income	11,439	8,691	6,899	2,501	-265	3,916
Income Tax Expense	2,035	1,650	938	-792	-380	772
Net Income	9,399	7,035	5,955	3,288	112	3,196
Net Income Growth	45%	18%	81%	2,836%	-97%	139%
Shares Outstanding (Diluted)	1,561	1,563	1,562	1,560	1,427	1,313
Shares Change (YoY)	0%	0%	0%	9%	9%	1%
EPS (Diluted)	6.02	4.5	3.81	2.11	0.08	2.43
EPS Growth	45%	18%	81%	2,538%	-97%	136%
Free Cash Flow	9,567	7,275	6,567	7,237	3,763	2,193
Free Cash Flow Per Share	6.12	4.65	4.2	4.63	2.63	1.67
Gross Margin	81.89%	82.13%	82.38%	80.49%	74.49%	80.2%
Operating Margin	24.34%	23.45%	19.46%	19.9%	13.1%	16.52%
Profit Margin	16.16%	13.01%	12.99%	7.41%	0.29%	12%
Free Cash Flow Margin	16.45%	13.45%	14.33%	16.31%	10.05%	8.23%
EBITDA	18,214	16,548	12,782	12,922	7,946	6,296
EBITDA Margin	31.33%	30.6%	27.9%	29.13%	21.23%	23.65%
D&A For EBITDA	4,064	3,865	3,866	4,094	3,044	1,897
EBIT	14,150	12,683	8,916	8,828	4,902	4,399
EBIT Margin	24.34%	23.45%	19.46%	19.9%	13.1%	16.52%
Effective Tax Rate	17.79%	18.98%	13.59%	-31.66%	143.39%	19.71%